Page 87 - 2020_09-Haematologica-web

Ruxolitinib and interferon-a for PV and MF
Spleen size
In nine patients, five with PV and four with MF, palpa- ble splenomegaly was present at baseline. After 2 years, four of these patients no longer had palpable splenomegaly, two had reduced palpable splenomegaly, one had increased palpable splenomegaly, and two had discontinued treatment. In one of the two patients who dropped out, palpable splenomegaly was reduced before drop-out; in the other, it increased. Spleen size, measured by sonography, was reduced during treatment (P<0.001)
(Online Supplementary Figure S2), and after 2 years of ther- apy, spleen size was reduced by 10% (95% CI: 6-15%). The reduction was statistically significant for PV patients at all time points, but not for MF patients at 6 months and subsequently (Online Supplementary Figure S2).
Molecular response
We observed statistically significant reductions in the JAK2 V617F allele burden at all time points (P<0.001) (Figure 3A). The median JAK2 V617F allele burden after 2
AB
CD
EFG
Figure 1. Response evaluations and peripheral blood cell remission. (A) Response evaluations after 2 years of treatment in patients with polycythemia vera (PV) or myelofibrosis (MF). Responses are classified as complete remission (CR), partial remission (PR), no response (NR), progressive disease (PD), drop-outs (DO), and, for MF patients, clinical improvement (CI) and stable disease (SD) (B) Kaplan-Meier plot depicting the cumulative incidence of peripheral blood count remission (PBCR) in patients not in PBCR at baseline (n=42). (C, D) Distribution of participants in PBCR and the number of patients dropping out of the protocol, patients with PV, and patients with MF. (E-G) Estimated change, with 95% confidence interval, in hematocrit (HCT) (E), white blood cell count (WBC) (F), and platelet count (PLT) (G), using generalized linear mixed models.
haematologica | 2020; 105(9)
2265